Skip to content

Total debt at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
$75.03M+37.8%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$9.16M+32.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.38M+29.5%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$808K+159%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Computed from long term debt + current portion long term debt + short term borrowings + operating lease liabilities + finance lease liabilities + financing obligations: $479K.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s total debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s total debt?
Climb Bio, Inc. (CLYM) reported total debt of $479K in Q1 2026.
How has Climb Bio, Inc.'s total debt changed year-over-year?
Climb Bio, Inc.'s total debt increased by 1.1% year-over-year, from $474K to $479K.
What is the long-term trend for Climb Bio, Inc.'s total debt?
Over 4 years (2021 to 2025), Climb Bio, Inc.'s total debt has grown at a -11.9% compound annual growth rate (CAGR), from $900K to $541K.
What does total debt mean?
Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.